"While it's been rather frustrating that management has not provided any color from the ongoing Phase 2, one has to think BMD impact was considered when deciding dose levels for the Phase 2 trial." ...

Edgewise Therapeutics' stock soars on positive Becker Muscular Dystrophy trial results. Learn why EWTX is a promising buy with derisked programs.

except possibly in the terminal phase of the missiles as they approach their targets. Fortunately, that strategy to secure the political viability of Aegis BMD worked — but perhaps too well.

including Becker Muscular Dystrophy (BMD) and Duchenne Muscular Dystrophy (DMD). EDG-7500 is Edgewise's most advanced program, currently in Phase 2 clinical trials for the treatment of HCM.

Bolland and colleagues previously conducted a 2-year controlled ... with the extension phase on the same treatment regime (active treatment, n = 57; placebo, n = 65). BMD was measured at half ...

A phase III trial that compared bazedoxifene, a novel selective estrogen receptor modulator, with raloxifene and placebo has shown that bazedoxifene prevents bone loss and increases BMD in ...